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Summary
 
CD8
 
1
 
 T lymphocytes recognize antigens as short, MHC class I-associated peptides derived by
processing of cytoplasmic proteins. The transporter associated with antigen processing translo-
cates peptides from the cytosol into the ER lumen, where they bind to the nascent class I mol-
ecules. To date, the precise location of the class I-TAP interaction site remains unclear. We
provide evidence that this site is contained within the heavy chain 
 
a
 
3 domain. Substitution of
a 15 amino acid portion of the H-2D
 
b
 
 
 
a
 
3 domain (aa 219-233) with the analogous MHC class
II (H-2IA
 
d
 
) 
 
b
 
2 domain region (aa 133-147) results in loss of surface expression which can be
partially restored upon incubation at 26
 
8
 
C in the presence of excess peptide and 
 
b
 
2-microglob-
ulin. Mutant H-2D
 
b
 
 (D
 
b
 
219-233) associates poorly with the TAP complex, and cannot present
endogenously-derived antigenic peptides requiring TAP-dependent translocation to the ER.
However, this presentation defect can be overcome through use of an ER targeting sequence
which bypasses TAP-dependent peptide translocation. Thus, the 
 
a
 
3 domain serves as an im-
portant site of interaction (directly or indirectly) with the TAP complex and is necessary for
TAP-dependent peptide loading and class I surface expression.
ˇ c
´ c
 
T
 
he MHC class I molecule is a heterotrimeric complex
comprised of a 44-kD heavy chain, 
 
b
 
2-microglobulin
(
 
b
 
2m; 12-kD light chain),
 
1
 
 and a peptide of 8–10 residues
(1–4). This complex is recognized by CD8
 
1
 
 T cells when
displayed on the surface of cells. Assembly of class I mole-
cules occurs in the endoplasmic reticulum (ER) when the
newly synthesized heavy chain associates with resident ER
chaperone calnexin, which facilitates folding and disulfide
bridge formation of the heavy chain and promotes its bind-
ing to 
 
b
 
2m (5, 6). Class I–
 
b
 
2m dimers then associate with a
heterodimeric, ER membrane protein called TAP (for
transporter associated with antigen processing), which con-
sists of TAP1 and TAP2. TAP transports peptides which
are predominantly derived from cytosolic proteins into the
ER lumen in an ATP-dependent manner (7, 8).
Physical association of class I heavy chain–
 
b
 
2m dimers
with TAP as determined by coprecipitation studies (9–12)
suggests a specific role of TAP in delivering peptides di-
rectly to the MHC class I. It is not clear at present whether
TAP associates with MHC class I directly or via an adaptor
molecule. A recently described protein, tapasin, is required
for class I interaction with TAP (13–17) and has more re-
cently been shown to be necessary for 
 
b
 
2m association
with TAP (18). Thus, tapasin can be described as a molecu-
lar bridge between class I and TAP molecules. Studies on
the role of tapasin have been carried out using human cell
lines and although tapasin seems to be required for proper
class I assembly and subsequent expression in these cell
lines, a murine counterpart for tapasin remains to be identi-
fied. 
Peptide loading of MHC class I can also occur in a TAP-
independent manner, as evidenced by the surface expres-
sion on TAP-deficient cells of class I molecules that are
loaded with signal sequence-derived peptides (19, 20).
However, this TAP-independent peptide loading seems to
be a minor pathway as it is relevant for a limited set of
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; ER, endoplasmic
reticulum; ES, E3/19K leader/signal sequence; NEPHGE, nonequilib-
rium pH-gradient gel electrophoresis; NP, nucleoprotein; RP10, RPMI
1640/10% FCS; TAP, transporter associated with antigen processing; VV,
vaccinia virus; wt, wild type.
  
866
 
TAP Interaction with Class I Heavy Chain 
 
a
 
3 Domain
 
MHC class I alleles that can bind signal sequence peptides,
and the diversity of the bound peptides is very limited (19,
20). Once localized to the ER lumen, peptides can bind to
and thereby stabilize nascent class I molecules. Peptide
binding results in the release of the class I molecule from
the ER (9, 10) and subsequent transport to the cell surface
via the exocytic pathway. The majority of misfolded, in-
completely assembled, or empty class I molecules are re-
tained in the ER from where they are removed to the cy-
tosol and degraded by the proteasome (21).
Thus, association of class I heavy chain–
 
b
 
2m with the
TAP complex (TAP1, TAP2, and possibly tapasin) appears
to be a critical event in MHC class I assembly. The location
of the site of interaction on class I with TAP complex re-
mains uncertain. Both the extracellular (22) and the trans-
membrane region/cytoplasmic tail (23) have been impli-
cated in this interaction. Point mutations introduced in the
 
a
 
3 domains of both H-2L
 
d
 
 and H-2D
 
d
 
 resulted in the loss
of TAP coprecipitation with the class I heavy chain (11,
22). However, these same point mutations do not affect the
ability of these molecules to be expressed at the cell surface
(24–26) and to present endogenous peptides (26), in con-
trast to mutations in either TAP or 
 
b
 
2m that drastically af-
fect both cell surface expression and antigen presentation of
MHC class I (27–30). Evidence is presented here that phys-
ical association with the TAP complex, TAP-dependent
peptide loading, and cell surface expression of class I is
completely abolished by a 15–amino acid substitution made
in the H-2D
 
b
 
 
 
a
 
3 domain. Thus, this region could define an
interaction site on the murine class I heavy chain with the
TAP complex.
 
Materials and Methods
 
Generation of Chimeric H-2D
 
b
 
 Constructs. 
 
PCR overlap ex-
tension was used to create H-2D
 
b
 
 cDNA with substitutions in the
 
a
 
3 domain. For the 62–amino acid replacement mutant, class I
 
a
 
3 domain base pairs 666–849 (cDNA) were replaced with class
II 
 
b
 
2 domain base pairs 2830–3013 (genomic DNA). The latter
fragment was obtained using the genomic H-2IA
 
b
 
d
 
 as template
and the following primers: sense 
 
5 
 
5
 
9
 
-GAGAGATCTAAC-
CACCACAAC-3
 
9
 
, antisense 
 
5 
 
5
 
9
 
-GGTACACACGGCATGT-
GTAGACCTCTCCCTG-3
 
9
 
. The product of this amplification
and the H-2D
 
b
 
 cDNA were used as templates in a subsequent re-
action where the H-2IA
 
b
 
d
 
 sequence was sewn to the base pairs
850–1097 portion of the H-2D
 
b
 
 using the same sense primer as
above and 5
 
9
 
-GGATCCACGCTTTACA-3
 
9
 
 as a reverse primer.
For the 15–amino acid replacement mutant, class I 
 
a
 
3 domain
base pairs 736–780 were replaced with class II 
 
b
 
2 domain base
pairs 2900–2944 using H-2D
 
b
 
 cDNA as template. The base pairs
751–1097 mutant portion of the gene was generated with the
sense 
 
5 
 
5
 
9
 
-TCATCCACACAGCTTAGGCCTGCAGGGGAT-
3
 
9
 
, and antisense 
 
5 
 
5
 
9
 
-GGATCCACGCTTTACA-3
 
9
 
. The am-
plification product was extended using sense 5
 
9
 
-GAGACAGT-
GGGGGTCTCATCCACACAGCTT-3
 
9
 
 and the same antisense
primer to obtain the 736–1097 base pair gene fragment. The 1–750
mutant fragment was obtained using sense 5
 
9
 
-GGATCCCAGA-
TGGGG-3
 
9
 
 and antisense 5
 
9
 
-GACCCCCACTGTCTCCTC-
CTGGCCATTCCTCTGCCAGGTCAGGGT-3
 
9
 
 primers. The
1–750 and 736–1097 base pair fragments were then sewn using
sense 
 
5 
 
5
 
9
 
-GGATCCCAGATGGGG-3
 
9
 
 and antisense 
 
5 
 
5
 
9
 
-GGA-
TCCACGCTTTACA-3
 
9
 
 primers. 
PCR products were inserted into the pGEM vector (Promega,
Madison, WI) from which they were sequenced using the fol-
lowing primers: sense 
 
5 
 
5
 
9
 
-ACCGAGGTGTCTATGGACT-
TCTTGCCC-3
 
9
 
, antisense 
 
5 
 
5
 
9
 
-AAAAGCCACCACAGCTC-
CAATGATGGC-3
 
9
 
. The BglII, SacI fragment of pGEM (now
containing cDNA for mutant H-2D
 
b
 
) was used to replace the
BglII, SacI fragment from the wild-type (wt)H-2D
 
b
 
 cDNA con-
tained in the Bluescript vector. The NotI, SacI fragment from
Bluescript-mutant H-2D
 
b
 
 then replaced the corresponding por-
tion of the wtD
 
b
 
 in the pCMU-D
 
b
 
 plasmid (31). The BamHI-
digested 1.1-kb fragment from pCMU-D
 
b
 
 was then inserted in
the appropriate orientation into the BamHI cloning site of the
pH
 
b
 
 APr-I-neo expression vector and transfected into P815 cells
by electroporation as described previously for the wtH-2D
 
b
 
 (32).
 
Reverse Transcription PCR. 
 
Total RNA was isolated from 5 
 
3
 
10
 
6
 
 cells using TRIzol reagent (GIBCO BRL, Gaithersburg, MD)
following the manufacturer’s protocol. cDNA was synthesized
using the Superscript preamplification system for first-strand
cDNA synthesis (GIBCO BRL). PCR was carried out using Taq
polymerase (Fisher Scientific, Fairlawn, NJ) and 20 
 
m
 
g/ml of
each primer. Amplification was conducted for 30 cycles. Each cy-
cle consisted of 60 s at 94
 
8
 
C, 60 s at 60
 
8
 
C, and 90 s at 72
 
8
 
C. The
following primers were used: for 
 
b
 
-actin, sense 
 
5 
 
5
 
9
 
-GTGGG-
CGCCCCAGGCACCA-3
 
9
 
, antisense 
 
5 
 
5
 
9
 
-CTCCTTATTGT-
CACGCACGATTTC-3
 
9
 
; for H-2D
 
b
 
, sense 
 
5 
 
5
 
9
 
-TACCTGC-
AGTTCGCCTATGAA-39, antisense 5 59-TGATGGCCATA-
GCTCCAAGGA-39 (PCR products were sequenced using these
same primers); for neomycin, sense 5 59-GCGGCGGCTG-
CATAC-39, antisense 5 59-TCATAGAAGGCGGCGG-39. One
fifth of each PCR sample was loaded onto a 0.8% agarose gel and
visualized by ethidium bromide staining.
Cell Lines.  P815 transfectants were maintained in RPMI
1640/10% FCS (RP10) supplemented with 500 mg/ml Geneticin
(GIBCO BRL). The influenza A/PR8/34 nucleoprotein (NP)
peptide 366-374–specific CTL line, PR8.2 (29) was maintained
by weekly restimulations with irradiated C57/BL6 spleen cells
pulsed with 10 mM influenza NP peptide (ASNENMETM) in
RP10 containing 5% rat Con A supernatant. 
To generate CTLs specific for endogenous influenza peptide,
C57BL/6 mice were immunized with influenza strain A/PR8/34
(a gift from Dr. A. Garcia-Sastre, Mt. Sinai Medical Center, New
York) by intraperitoneal injection and spleens were harvested af-
ter 10 d and stimulated in vitro for 5–6 d with virus-infected, au-
tologous splenocytes. These CTLs were used in cytotoxicity as-
says using recombinant vaccinia constructs.
Cytotoxicity Assays. Target cells were pulsed with [51Cr]so-
dium chromate in RP10 medium for 1 h at 378C, washed twice
with PBS, and plated at 104 cells/well of a 96-well round-bot-
tomed plate. Influenza NP 366–374 peptide as well as effector
cells (CTLs) were then added to the wells to a final volume of
200 ml/well. After a 4-h incubation at 378C, 100 ml of the super-
natants were harvested and 51Cr-release was measured. Where flu
peptide concentrations range from 1 nM to 10 mM, the effector
to target ratio was kept constant at 10:1. 
For induction of class I expression, P815 transfectants (targets)
were incubated overnight at 268C in serum-free medium (Opti
MEM I; GIBCO BRL) in the presence of 10 mM NP 366–374
peptide with or without human b2m (Sigma Chemical Co., St.
Louis, MO) at 5 mg/ml. Cells were then pulsed with 51Cr,
washed three times with PBS, and plated at 104/well. CTL assays867 Kulig et al.
were carried out as above with effector to target ratios starting at
100:1 with serial, threefold dilutions of effector cells.
Flow Cytometry.  2–5  3  105 P815 and P815 transfectants
were washed once in PBS/2% FCS followed by incubation with
a saturating amount of biotinylated anti–H-2Db antibody (KH95;
PharMingen, San Diego, CA) for 30 min at 48C. Cells were
washed twice with PBS/2% FCS and then suspended in 100 ml of
a 1:100 dilution of streptavidin-PE (Caltag Labs., South San Fran-
cisco, CA). Cells were washed twice and resuspended in 300 ml
PBS/1% formaldehyde. All samples were analyzed using a FAC-
ScanÒ flow cytometer (Becton Dickinson, Mountain View, CA).
Generation of Vaccinia Constructs.  To produce the NP 366–374
recombinant vaccinia virus (VV), complementary oligonucle-
otides were designed and synthesized to insert into a modified
pSC11 plasmid (33). The plus strand (1) was composed of the
following bases: TCGACCACCATGGCTTCCAATGAAAA-
TATGGAGACTATGTGATAGGTACCGC. This sequence en-
coded an insertional SalI site extension (TCGA), Kozak’s se-
quence (CCACC), a methionine initiation triplet (ATG), nine
triplet bases coding for the desired antigenic determinant (ASN-
ENMETM), two stop codons (TGA and TAG), and an insertional
NotI site (GC). The complementary minus strand (2) was com-
posed of the following bases: GGCCGCGGTACCTATCACA-
TAGTCTCCATATTTTCATTGGAAGCCATGGTGG. The
plus and minus strand oligonucleotides were annealed to create
double-stranded DNA with SalI and NotI cloning sites and in-
serted into the modified version of pSC11 downstream of the
early/late VV p7.5 promoter. 
The E3/19K leader/signal sequence (ES) NP 366–374 recom-
binant vaccinia virus was constructed by inserting synthetic oligo-
nucleotides (StyI–NotI double-stranded DNA fragment) behind
the ES cloned into pSC11 (33, 34). All oligonucleotide insertions
into the pSC11 plasmids were confirmed by DNA sequencing.
Finally, recombinant vaccinia viruses were generated in CV-1
cells by homologous recombination, plaque-purified at least three
times, and propogated in thymidine kinase-deficient human 143B
osteosarcoma cells as described (35).
Immunoprecipitations.  Metabolic labeling, immunoprecipita-
tion, and 2D nonequilibrium pH-gradient gel electrophoresis
(NEPHGE)–PAGE were performed in essence as previously de-
scribed (36, 37), except that 1% digitonin was used instead of
0.5% NP-40. Antibodies used for precipitation were obtained as
follows: the anticalnexin antiserum was purchased from Stressgen
(Victoria, Canada), the anti–heavy chain serum (38) was obtained
from H. Ploegh (Massachusetts Institute of Technology, Boston,
MA), and anti-TAP antisera were produced by immunizing rab-
bits with purified recombinant mouse TAP1 or TAP2-GST fu-
sion proteins, and will be described in detail elsewhere (Nandi,
D., and J.J. Monaco, manuscript in preparation).
Results
Mutant H-2Db Molecules Are Not Expressed at the Cell Sur-
face at Detectable Levels. Sequences from the b2 domain of
the mouse MHC class II H-2IAbd gene were substituted
into the a3 domain of the class I H-2Db gene using a PCR
overlap extension mutagenesis strategy. The class II b2 do-
main was chosen to substitute for the class I a3 domain due
to its predicted structural homology to the a3 domain (39).
Two such chimeric H-2Db constructs were created, one
with an exchange of 15 amino acids and the other with a
62–amino acid replacement (Fig. 1 A). Due to sequence
homology between these class I and II domains, the actual
change in the number of amino acids is 11 and 42, respec-
tively. However, we will refer to these molecules as 15–
(Db219–233) and 62– (Db196–257) amino acid replace-
ments in keeping with the total number of class II residues
introduced.
The 15– and 62–amino acid mutant constructs as well as
a wtH-2Db construct were transfected into the P815 mu-
rine mastocytoma cell line (H-2d) and screened for expres-
sion of the mutant molecules at the messenger RNA level
using reverse transcription PCR. RNA was isolated and
cDNA synthesized from each of the 15– and 62–amino
acid mutant P815 transfectants (designated P815-Db219–
233 and P815-Db196–257, respectively) as well as from
nontransfected P815 and wtDb P815 transfectants. The
cDNA was amplified in a PCR using primers specific for
the H-2Db molecule, but non–cross-reactive with H-2Ld,
which is also expressed on P815 and shares 94% identity
with H-2Db. The primers amplify a 558-bp fragment en-
compassing the region where the H-2IAd sequence is
flanked by the H-2Db sequence. The products of this PCR
amplification (Fig. 1 B) were verified by sequencing. 
Despite expression of mutant H-2Db molecules at the
messenger RNA level, immunofluorescence staining for
H-2Db resulted in no detectable surface expression as com-
pared with the wildtype control (Fig. 1 C). To test for po-
tentially low levels of surface expression, transfectants were
used as targets in a cytotoxicity assay that is generally more
sensitive than FACSÒ analysis. The CD8 coreceptor-inde-
pendent CTL line PR8.2, which is specific for the H-2Db–
restricted influenza NP 366–374 peptide was used in a
51Cr–release assay where the level of killing of mutant
transfectant targets pulsed with peptide was compared with
that of P815-wtDb controls. Neither mutant molecule
could sensitize P815 cells for lysis in the CTL assay (Fig. 1
D), demonstrating that the steady-state levels of mutant
heavy chains available for peptide binding were below the
detectable threshold for a CTL assay.
Mutant H-2Db Molecules Can Be Stabilized at the Cell Sur-
face. To test whether mutant heavy chains that may be
reaching the cell surface in very limited quantities could be
captured and stabilized at the cell surface, transfectants were
incubated overnight at 268C in the presence of excess influ-
enza NP 366–374 peptide and b2m. Transfectants were
then labeled with 51Cr and used in the influenza peptide–
specific cytotoxicity assay. The results show that P815-
Db219–233 was lysed comparably to P815-wtDb, but that
P815-Db196–257 was not specifically lysed (Fig. 2 A). We
conclude that the 15–amino acid mutant H-2Db molecules
can be stabilized at the cell surface by addition of exoge-
nous peptide and b2m and that the stabilized molecule can
present antigenic peptide to CTLs, suggesting that it is not
grossly misfolded. The phenotype of the Db196–257 is
much more severe, however, perhaps due to misfolding of
the molecule. Subsequent studies were carried out using
only the P815-Db219–233 transfectant.
To determine whether incubation at 268C and addition
of exogenous peptide and b2m can upregulate surface ex-868 TAP Interaction with Class I Heavy Chain a3 Domain
pression enough to be detected by FACSÒ analysis, trans-
fectants treated in this manner were stained with an anti-
body against the H-2Db molecule. The FACSÒ results
indicate that surface expression of the 15–amino acid mu-
tant molecule can be detected at a level comparable to that
of P815-wtDb maintained at 378C (Fig. 2 B). In fact, mere
incubation at 268C in the absence of peptide (but presence
of b2m) results in significant upregulation of Db219–233
cell surface expression.
To exclude the possibility of a randomly linked mutation
related to general antigen processing and/or class I assem-
bly, we examined the surface expression of H-2Kd in P815,
P815-wtDb, and P815-Db219–233. Comparable levels of
H-2Kd were seen in these cells (data not shown) suggesting
that the defect in proper class I assembly is restricted to the
mutant heavy chain.
Upregulation of Surface Expression of Mutant H-2Db Mole-
cules Requires b2m. The 15–amino acid mutant contains
substitutions within the class I a3 domain that could possi-
bly affect the ability of b2m to bind to the heavy chain.
Substituted amino acid positions 231 and 233 are thought
to be 2 of the 13 contact sites between the a3 domain and
b2m (40). However, the a1 and a2 domains contain 11
and 13 potential b2m interaction sites, respectively, so it
seems unlikely that a change in only two b2m contact sites
would abrogate its interaction with the heavy chain. Still, it
is conceivable that substitutions made at these positions
could negatively affect the overall interaction between the
heavy chain and b2m to a degree such that proper class I
assembly in the ER does not occur, resulting in intracellu-
lar retention of the molecule. However, the fact that mu-
tant H-2Db molecules are stabilized by addition of peptide
and b2m suggests that these molecules are capable of asso-
ciation with b2m. In fact, an appreciable upregulation of
surface expression is seen only in the presence of exoge-
nous b2m and cannot be seen by the addition of peptide
alone (data not shown). Lack of upregulation of surface ex-
pression by peptide alone is also evident when cells treated
in this manner are used as targets in a CTL assay (Fig. 3).
These results suggest that the mutant H-2Db heavy chain is
able to associate with b2m.
Mutant H-2Db Molecules Are Deficient in TAP-dependent
Peptide Loading. The phenotype of the mutant H-2Db
transfectants is reminiscent of that of the cell line RMA-S
Figure 1. Db219–233 and Db196–257 mutant heavy chains are not expressed at the cell surface. (A) Amino acid sequence (single letter code) of the
portions of the a3 H-2Db heavy chain aligned to the homologous sequences of the b2 domain of H-2IAd. Db219–233 and Db196–257 mutant heavy
chains were generated by substituting indicated portion of the H-2Db a3 domain with the corresponding region from the H-2IAd b2 domain. (B) Re-
verse transcription PCR analysis of the H-2Db, neomycin resistance, and b-actin expression in P815, P815-wtDb, P815-Db219–233, and P815-Db196–
257 cells. (C) Immunofluorescence analysis of P815, P815-wtDb, P815-Db219–233, and P815-Db196–257 cells cultured at 378C. Cells were stained with
biotinylated anti–H-2Db–specific monoclonal antibody followed by streptavidin-PE. Bold lines, cells stained with monoclonal antibody; plain lines, cells
stained with secondary reagent alone. (D) Cytotoxicity assay using influenza NP 366-374–specific H-2Db–restricted CD81 cell line as effector and 51Cr-
labeled P815-wtDb, P815-Db219–233, and P815-Db196–257 as target cells in the presence of indicated concentrations of the exogenous NP 366–374
peptide added directly to the assay.869 Kulig et al.
as well as other TAP-deficient cell lines or cells lacking
b2m (27–30). The low level of surface expression of class I
on RMA-S is due to deficient peptide loading via the TAP
complex. To determine whether a similar deficiency may
be occurring in P815-Db219–233, these cells were infected
with recombinant vaccinia virus containing a minigene
construct for the H-2Db–restricted influenza epitope (NP
366–374), which was either linked COOH terminally to
an ER insertion sequence (VV ES-NP) or not (VV NP).
The linking of an ER insertion sequence to the peptide al-
lows for TAP-independent peptide translocation to the ER
(41, 42). If the inability of the mutant H-2Db molecule to
be loaded with peptide is due to a disruption in its associa-
tion with TAP, infection with the vaccinia construct con-
taining the ER insertion signal linked to the influenza pep-
tide minigene should bypass TAP-dependent peptide loading
of the molecule. The use of these vaccinia-infected cells as
targets in the flu-specific CTL assay shows that P815-
Db219–233 targets infected with the VV ES-NP were spe-
cifically killed, but those infected with the VV NP were
not (Fig. 4). Infection with either VV ES-NP or VV NP
rendered P815-wtDb targets equally susceptible to lysis,
whereas parental P815 were not lysed after infection with
either of the vaccinia constructs (Fig. 4). These results
demonstrate that TAP-dependent peptide transport to the
mutant H-2Db molecule is specifically impaired. In addi-
tion, these results reconfirm the fact that the mutant heavy
chain is capable of association with b2m. Thus, the a3 do-
main of class I must contain important sites of interaction
either directly or indirectly with TAP that are critical for
proper peptide loading and subsequent surface expression
of class I molecules.
TAP Does Not Associate with the 15–Amino Acid Mutant
H-2Db Molecules. The above results, showing a functional
defect in TAP-dependent peptide loading of the Db219–
233 molecule, suggest that the mutant heavy chain may be
incapable of physical association with the TAP complex.
To test this, immunoprecipitation of [35S]methionine-
labeled P815, P815-wtDb, or P815-Db219–233 was carried
out using antibodies specific for MHC class I heavy chain,
calnexin, TAP1, or TAP2. Immunoprecipitates were re-
solved using 2D NEPHGE-PAGE. Immunoprecipitation
of parental P815 cell lysate using heavy chain– and cal-
nexin–specific antibodies revealed distinct spots that were
identified based on their predicted mobility to correspond
to the H-2Kd (mol wt 5 39,368 daltons; pI 5 6.43), H-2Dd
(mol wt 5 37,278 daltons; pI 5 5.13), and H-2Ld (mol wt
5 38,400 daltons; pI 5 6.20) heavy chains (Fig. 5 A). The
same heavy chain pattern was observed when TAP-1– or
TAP-2–specific antibodies were used for immunoprecipi-
tation (Fig. 5 B). In addition, b2m can be identified in all
precipitates, as well as several spots that, based on their mo-
lecular weight, could correspond to tapasin. However, since
the sequence of mouse tapasin is not yet published, we do
not know which of these, if any, represent tapasin. Precipi-
tation of P815-wtDb lysate with anti–heavy chain or anti-
calnexin antibodies did not reveal an additional distinct
class I heavy chain, but resembled the pattern seen with
Figure 2. Low temperature,
peptide, and b2m upregulate
the Db219–233 at the cell sur-
face. (A) Cytotoxicity assay using
influenza NP 366-374–specific
H-2Db–restricted CD81 cell line
as effector and 51Cr-labeled P815,
P815-wtDb, P815-Db219–233,
and P815-Db196–257 as target
cells. All targets were preincu-
bated overnight at 268C in the
presence of 10 mM NP 366–374
and 5 mg/ml human b2m. Effec-
tor to target ratio was 10:1. (B)
Immunofluorescence analysis of
P815, P815-wtDb, and P815-
Db219–233 cells. P815 and P815-
wtDb were cultured at 378C,
whereas P815-Db219–233 cells
were cultured at 268C in the absence or presence of NP 366–374 plus b2m. Cells were stained with biotinylated anti–H-2Db–specific monoclonal anti-
body followed by streptavidin-PE. Bold lines, cells stained with monoclonal antibody; plain lines, cells stained with secondary reagent alone.
Figure 3. Presentation of NP 366–374 to specific CD81 cells by
Db219–233 requires the presence of b2m. P815, P815-wtDb, and P815-
Db219–233 cells were incubated overnight at 268C in the absence of fetal
calf serum. 10 mM NP 366–374 and/or 5 mg/ml human b2m were added
as indicated. Cells were then labeled with 51Cr and used in a cytotoxicity
assay with an NP 366-374–specific CD81 cell line as effector cells.870 TAP Interaction with Class I Heavy Chain a3 Domain
P815 (data not shown). This is most likely due to the indis-
tinguishable migration patterns of H-2Db and H-2Ld be-
cause of their extensive sequence homology. However,
Db219–233 is predicted to migrate significantly differently
(mol wt 5 38,295 daltons; pI 5 7.19), and should be ob-
served as a distinct spot. Indeed, precipitation of P815-
Db219–233 lysate using anti–heavy chain antibodies re-
vealed a new spot with a migration pattern expected for the
mutant H-2Db molecule (Fig. 5 A). Based on the intensity
of this spot, we conclude that Db219–233 is synthesized at a
level comparable to the three endogenous heavy chains (H-
2Kd, H-2Ld, and H-2Dd). However, anti-TAP antibodies
precipitated significantly lower amounts (if any) of Db219–
233 compared with the endogenous heavy chains (Fig. 5
B). In contrast to what is seen in the TAP immunoprecipi-
tates, more Db219–233 relative to the endogenous heavy
chains appears associated with calnexin (Fig. 5 A), consis-
tent with the data in the previous figures indicating that this
molecule fails to traffic efficiently to the cell surface and,
hence, accumulates in the ER.
Discussion
We have shown that substitution of amino acids 219–
233 within the a3 domain of H-2Db results in the loss of its
expression at the cell surface. Cell surface expression of
Db219–233 can be rescued by incubation at 268C with ad-
dition of excess peptide and b2m. The rescued molecule is
functional in its ability to present exogenous peptide for
recognition by CD81 T cells, suggesting that substitutions
introduced into the a3 domain do not grossly affect the
conformation of the molecule. P815-Db219–233 exhibits a
phenotype very similar to that of RMA-S cells, which led
us to believe that the defect of Db219–233 expression is
due to a lack of TAP-dependent peptide loading. This was
demonstrated by the ability of Db219–233 to present en-
dogenous influenza NP 366–374 peptide only when it is
linked COOH terminally to an ER insertion sequence,
thus allowing it to bypass the requirement for TAP-depen-
dent peptide loading. Finally, the functional defect in TAP-
mediated peptide translocation to Db219–233 correlates
with the finding that physical association of Db219–233
with the TAP complex is drastically reduced. Together,
these results argue that amino acids 219–233 of the a3 do-
main serve as an important docking site for the TAP com-
plex during the assembly of MHC class I molecules.
Although human b2m is clearly binding to Db219–233,
as evidenced by the requirement for human b2m to stabi-
lize the Db219–233 at the cell surface (Fig. 3), this does not
necessarily reflect the ability of mouse b2m to bind Db219–
233. Still, the fact that antigen presentation by Db219–233
occurs when peptides are targeted to the ER in a TAP-
independent manner (Fig. 4) provides evidence that mouse
b2m too is binding to the mutant heavy chain. If the lack
of Db219–233 surface expression and antigen presentation
were due to impaired b2m binding, the phenotype would
remain consistent, even when peptides are targeted to the
ER by linkage to an ER insertion sequence. 
 It has been previously suggested that TAP may associate
with the a3 domain of the class I heavy chain. This was
based on findings that substitution of a single amino acid
within the a3 domain (H-2Ld227 or H-2Dd222) can result
in the loss of class I association with TAP, as determined in
coprecipitation studies (11, 22). However, these molecules
are still present at the cell surface at levels detectable by
FACSÒ analysis (24–26) and are able to present endogenous
peptides (26), suggesting that a true loss of TAP-dependent
peptide loading has not occurred. Still, the loss of class I–TAP
association as detected in immunoprecipitations using H-2Ld
227 and H-2Dd 222 hints to the a3 domain as an important
site of interaction with the TAP complex. It is known that
the association between TAP and class I is very labile in
most detergents other than digitonin (10). Perhaps the
change of even one critical residue involved in TAP associ-
ation renders this interaction even more labile, even in
mild detergents. This change, however, must not abrogate
Figure 4. TAP-independent, but not
TAP-dependent, delivery of endogenous
antigens to Db219–233 sensitizes P815-
Db219–233 for lysis by NP 366-374–spe-
cific CTLs. Uninfected, VV NP–, or VV
ES-NP–infected P815, P815-wtDb, or
P815-Db219–233 cells were labeled with
51Cr and used as targets in a CTL assay.
Spleen cells of C57BL/6 mice infected with
influenza A/PR8/34, restimulated in vitro
with influenza A/PR8/34, were used as ef-
fector cells.
Figure 5. Reduced physical association of Db219–233 with TAP. [35S]methionine-labeled P815 or P815-Db219–233 lysates immunoprecipitated with
MHC class I heavy chain–, calnexin–, TAP-1–, or TAP-2–specific antibodies. Immunoprecipitates were resolved using 2D NEPHGE-PAGE. Arrows, spots
corresponding to H-2Kd, H-2Dd, H-2Ld, and H-2Db219–233 b2m. (B) Circles, the expected position of H-2Db219–233.871 Kulig et al.872 TAP Interaction with Class I Heavy Chain a3 Domain
the in vivo function of TAP in loading peptide onto class I.
This could explain why H-2Ld227 and H-2Dd222 are still
expressed and function normally at the cell surface, yet are
shown by immunoprecipitation not to associate with TAP.
Perhaps caution must be taken when interpreting the re-
sults of immunoprecipitations that indicate a lack of TAP
association with class I molecules. This is further supported
by the findings of allelic variations in the ability of human
class I heavy chains to associate with TAP, as HLA-B35 al-
leles do not coprecipitate with TAP (43) and yet are ex-
pressed at the cell surface and present antigenic peptides ef-
ficiently (44, 45).
Point mutations of the a2 domain of the human class I
molecule HLA-A0201 (position 134) results in z80% re-
duced surface expression and diminished ability to present
endogenous antigens (46, 47), implicating the a2 domain
of the heavy chain in binding to TAP. However, the same
mutant molecule is rapidly transported to the cell surface
without bound peptides. Apparently, this molecule escapes
degradation that normally happens to the majority of par-
tially assembled class I molecules (21). It has therefore been
suggested that mutation at position 134 disrupts interaction
with an accessory molecule (such as calreticulin) responsi-
ble for sorting the peptide-free class I molecules to the deg-
radative pathway and/or ER retention of unloaded mole-
cules (48). Our results do not exclude the role of the a2
domain in contributing to class I association with TAP. In
fact, an a2 domain contact with the TAP complex could
enhance the association necessary for peptide transfer onto
the class I molecule. We do show, however, that a net
change of 11 amino acids within the a3 domain is suffi-
cient to dissociate class I from TAP function.
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